Open Beta
TREN
MetriLume
TREN

US marketsAIM

SEC-sourced researchBeta

AIM

AIM ImmunoTech Inc.

Company comparison ↗

Data passport

CIK
0000946644
Exchange
NYSE
Business activity
Biological Products, (No Diagnostic Substances) · SIC 2836
Financial inputs
6/6
Filing date
Sep 30, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 170,000.0000 USD; December 2025: 88,000.0000 USD170K USD0 USD0December 2024December 2025
AIM · Exact amounts and source periods · USD
Period endRevenueFiling date
December 2024170,000.0000Mar 27, 2026
December 202588,000.0000Mar 27, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202588,000.0000-13,958,000.0000-10,957,000.00005,782,000.000015,565,000.0000Mar 27, 2026
December 2024170,000.0000-17,320,000.0000-14,888,000.00008,608,000.00009,930,000.0000Mar 27, 2026

Explainable fundamental score

Five equally weighted components based on SEC financial inputs. No price inputs or personal investment preferences.

20/100
Profitability0
Growth2
Balance sheet0
Cash generation0
Data coverage100

Component weight: 20% · Minimum data coverage: 50% · Missing component value: 50/100

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$88KJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$170KJan 1, 2024 – Dec 31, 2024Mar 27, 202610-K
Net incomeNetIncomeLoss-$13.96MJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$10.96MJan 1, 2025 – Dec 31, 2025Mar 27, 202610-K
Total assetsAssets$5.78MDec 31, 2025Mar 27, 202610-K
Total liabilitiesLiabilities$15.57MDec 31, 2025Mar 27, 202610-K

New filings

Explore methodology ↗